CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.924
EU - Europa 9.295
AS - Asia 6.981
SA - Sud America 1.034
Continente sconosciuto - Info sul continente non disponibili 357
AF - Africa 257
OC - Oceania 18
AN - Antartide 1
Totale 28.867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.579
RU - Federazione Russa 4.144
SG - Singapore 2.816
CN - Cina 1.819
GB - Regno Unito 1.219
IT - Italia 1.184
BR - Brasile 788
VN - Vietnam 696
HK - Hong Kong 629
DE - Germania 595
SE - Svezia 458
FR - Francia 424
IE - Irlanda 383
FI - Finlandia 316
KR - Corea 234
CA - Canada 174
BD - Bangladesh 151
IN - India 150
NL - Olanda 142
PL - Polonia 93
JP - Giappone 88
AR - Argentina 85
ID - Indonesia 76
MX - Messico 68
UA - Ucraina 62
ES - Italia 57
TR - Turchia 50
ZA - Sudafrica 46
TG - Togo 42
NG - Nigeria 41
AT - Austria 40
IQ - Iraq 38
BJ - Benin 37
CO - Colombia 36
EC - Ecuador 35
BE - Belgio 30
VE - Venezuela 29
PK - Pakistan 26
CZ - Repubblica Ceca 24
MA - Marocco 24
CL - Cile 23
JM - Giamaica 20
PH - Filippine 19
CR - Costa Rica 18
LT - Lituania 18
UZ - Uzbekistan 17
IR - Iran 16
AU - Australia 15
CH - Svizzera 15
AE - Emirati Arabi Uniti 14
MY - Malesia 14
SA - Arabia Saudita 14
KZ - Kazakistan 13
PE - Perù 13
TN - Tunisia 13
JO - Giordania 12
EG - Egitto 11
HN - Honduras 11
NP - Nepal 11
PY - Paraguay 11
DK - Danimarca 10
KE - Kenya 10
NI - Nicaragua 9
TT - Trinidad e Tobago 9
AM - Armenia 8
AZ - Azerbaigian 8
LV - Lettonia 8
BO - Bolivia 7
CY - Cipro 7
DZ - Algeria 7
GR - Grecia 7
IL - Israele 7
KG - Kirghizistan 7
PT - Portogallo 7
RO - Romania 7
AL - Albania 6
EE - Estonia 6
NO - Norvegia 6
PS - Palestinian Territory 6
SK - Slovacchia (Repubblica Slovacca) 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
EU - Europa 5
GT - Guatemala 5
PA - Panama 5
RS - Serbia 5
SN - Senegal 5
SV - El Salvador 5
AO - Angola 4
HR - Croazia 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
SI - Slovenia 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
BG - Bulgaria 3
GA - Gabon 3
HU - Ungheria 3
OM - Oman 3
Totale 28.459
Salva come PNG Salva come JPEG
Città #
Ashburn 1.542
Singapore 1.464
Moscow 1.403
San Jose 1.344
Dallas 1.063
Southend 901
Chandler 819
Hong Kong 617
Council Bluffs 458
Verona 398
Beijing 382
Dublin 378
The Dalles 313
Woodbridge 299
Munich 269
Los Angeles 245
New York 244
Ho Chi Minh City 222
Jacksonville 201
Ann Arbor 181
Hanoi 157
Lawrence 125
Princeton 125
Helsinki 121
Santa Clara 118
Wilmington 116
Jinan 105
Houston 97
London 93
São Paulo 93
Buffalo 86
Milan 86
Redondo Beach 75
Tokyo 73
Turku 72
Tianjin 70
Sindelfingen 64
Shenyang 60
Chicago 59
Redmond 59
Orem 58
Frankfurt am Main 55
Meda 55
Nanjing 54
Columbus 53
Seoul 53
Amsterdam 52
Montreal 52
Seattle 52
Warsaw 51
Hebei 50
Brooklyn 49
Rome 45
Atlanta 44
Lomé 42
Washington 42
Guangzhou 40
Lappeenranta 40
Phoenix 40
Abuja 39
Jakarta 39
Toronto 39
Denver 38
Cotonou 37
McKinney 37
Boardman 35
Chennai 35
San Francisco 35
Stockholm 34
Nanchang 33
Da Nang 32
Kent 32
Zhengzhou 32
Hangzhou 31
Johannesburg 31
Brussels 30
Changsha 30
Nuremberg 30
Haikou 29
Bologna 27
Haiphong 27
Mexico City 27
Ningbo 27
Cleveland 25
Rio de Janeiro 25
Baghdad 23
Belo Horizonte 23
Boston 22
Dong Ket 22
Mumbai 22
Vienna 22
Shanghai 21
Biên Hòa 20
Naples 20
Paris 20
Poplar 20
Taiyuan 20
Taizhou 20
Barnet 19
City of London 19
Totale 16.673
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 323
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 264
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 263
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 254
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 250
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 234
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 225
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 221
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 216
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 210
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 207
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 206
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 206
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 205
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 204
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 204
A multimodal approach to cancer-related cachexia: from theory to practice 203
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 199
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 197
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 194
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 192
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 189
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 187
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 186
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 185
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 185
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 184
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 184
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 184
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 183
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 181
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 181
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 180
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 178
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 177
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 176
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 176
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 176
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 176
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 174
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 173
Exercise levels and preferences in cancer patients: a cross-sectional study 173
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 173
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 172
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 172
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 171
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 170
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 170
Do immune checkpoint inhibitors need new studies methodology? 168
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 167
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 167
A cross-sectional study exploring the perception of exercise oncology in the Italian population 166
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 166
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 165
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 165
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 164
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 163
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 163
Clinical meta-analyses of targeted therapies in adenocarcinoma. 162
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 161
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 160
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 160
Muscle derangement and alteration of the nutritional machinery in NSCLC 157
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 157
Physical activity guidelines in oncology: a systematic review of the current recommendations 156
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 156
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 156
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 155
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 154
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 152
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 151
Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study 151
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 151
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 151
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 149
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 148
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 147
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 145
Exercise and anemia in cancer patients: could make the difference? 145
Exercise oncology: It is time to make a change 145
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 144
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation 143
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 143
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 142
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 142
Exploring the feasibility of a combined exercise program for patients with advanced lung or pancreatic cancer 141
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 141
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 141
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 141
Physical activity and exercise in lung cancer care: will promises be fulfilled? 140
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 139
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 139
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 139
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 139
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 138
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 138
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers 136
Exercise and bone health in cancer: enemy or ally? 136
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 136
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 136
Totale 17.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.256
article - articoli 107.266
book - libri 0
conference - conferenze 1.196
curatela - curatele 0
other - altro 388
patent - brevetti 0
selected - selezionate 0
volume - volumi 406
Totale 218.512
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022720 0 0 0 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20254.541 230 184 209 791 148 200 201 192 708 351 435 892
2025/202614.490 848 732 1.103 2.374 3.708 849 1.305 813 1.195 925 318 320
2026/20271.895 207 452 520 716 0 0 0 0 0 0 0 0
Totale 28.867